Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 19, 2014Journal of Hematology & OncologyOpen Access

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNancy L. BartlettRCRobert ChenMFMichelle A. Fanale

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bartlett et al. (2014) studied this question.

synapsesocial.com/papers/69d97e215e5bcb4e3b836d60https://doi.org/10.1186/1756-8722-7-24
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma2012 · 1,536 citations
  2. 2Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study2012 · 1,001 citations
  3. 3Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma2013 · 29 citations
  4. 4Revised Response Criteria for Malignant Lymphoma2007 · 4,467 citations
  5. 5Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment2000 · 690 citations